Sie suchten nach: sapropterin (Englisch - Dänisch)

sapropterin dihydrochloride
sapropterindihydrochlorid

kuvan sapropterin dihydrochloride
kuvan sapropterindihydrochlorid

each tablet contains 100 mg of sapropterin
hver tablet indeholder 100 mg

the active substance is sapropterin dihydrochloride.
aktivt stof: sapropterindihydrochlorid.

- the active substance is sapropterin dihydrochloride.
det aktive stof er sapropterindihydrochlorid.

kuvan 100 mg soluble tablets sapropterin dihydrochloride
kuvan 100 mg opløselige tabletter sapropterindihydrichlorid

dihydrochloride (equivalent to 77 mg of sapropterin).
sapropterindihydrochlorid (svarende til 77 mg sapropterin).

the rate and extent of absorption of sapropterin is influenced by food.
hastighed og omfang af absorptionen af sapropterin er afhængig af fødeindtaget.

kuvan is a medicine that contains the active substance sapropterin dihydrochloride.
kuvan er et lægemiddel, der indeholder det aktive stof sapropterindihydrochlorid.

sapropterin dihydrochloride is primarily metabolised in the liver to dihydrobiopterin and biopterin.
sapropterindihydrochlorid metaboliseres hovedsageligt i leveren til dihydrobiopterin og biopterin.

emesis is considered to be related to the ph of the solution containing sapropterin.
emesis menes at relatere sig til sapropterinopløsningens ph.

the active substance in kuvan, sapropterin dihydrochloride, is a synthetic copy of bh4.
det aktive stof i kuvan, sapropterindihydrochlorid, er en syntetisk kopi af bh4.

following intravenous administration in rats, sapropterin dihydrochloride is mainly excreted in the urine.
efter intravenøs indgift i rotter af sapropterindihydrochlorid sker udskillelsen overvejende i urinen.

in rats, following intravenous radiolabeled sapropterin administration, radioactivity was found to distribute in foetuses.
efter intravenøs indgift af radioaktivt mærket sapropterin i rotter kunne radioaktivitet spores i fostrene.

each soluble tablet contains 100 mg of sapropterin dihydrochloride (equivalent to 77 mg of sapropterin).
hver opløselig tablet indeholder 100 mg sapropterindihydrochlorid (svarende til 77 mg sapropterin).

there was a significant difference in dietary phenylalanine tolerance in the sapropterin treatment group as compared to the placebo group.
der var en signifikant forskel i tolerancen over for fenylalaninindtaget via kosten i gruppen behandlet med sapropterindihydrochlorid sammenlignet ned placebogruppen.

in clinical studies of patients with bh4 deficiency treated with a preparation of sapropterin, convulsions and exacerbation of convulsions was observed.
i kliniske forsøg, hvor patienter med bh4 mangel blev behandlet med sapropterin, observeredes kramper og forværring af kramper.

sapropterin was found to be weakly mutagenic in bacterial cells and an increase in chromosome aberrations was detected in chinese hamster lung and ovary cells.
sapropterin fandtes svagt mutagent i bakterieceller og en øget kromosomafvigelse sås i lunge- og ovarieceller hos chinese hamster.

no increase in total biopterin concentrations in either foetuses or milk was observed in rats after oral administration of 10 mg/kg sapropterin dihydrochloride.
der sås ingen øgning af total biopterinkoncentrationer hverken i fostre eller i mælk hos rotter efter peroral indgift af 10 mg/kg sapropterindihydrochlorid.

headache and dizziness have been reported after the administration of sapropterin dihydrochloride above the recommended maximum dose of 20 mg/kg/day.
hovedpine og svimmelhed er indberettet efter indgift af sapropterindihydrochlorid over den anbefalede maksimum dosering på 20 mg/kg/dag.